The ADuong Stem Cell Transplant program is hiring! We are looking for an experienced clinical investigator to join our group. Please see our ads on the ASTCT and ASH websites for details and please reach out to me!

Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management onlinelibrary.wiley.com/doi/full/10.10… #leusm

⭐️ AML Pathways of treatment AJH 2025 AML Update on Diagnosis and Management - Frontline and Relapse by Shai Shimony Maximilian Stahl

American Journal of Hematology | Blood Research Journal | Wiley Online Library onlinelibrary.wiley.com/doi/full/10.10…

In this nonrandomized clinical trial, a simplified treatment algorithm and expert support system reduced early death rates in acute promyelocytic leukemia patients from 30% to below 15%. ja.ma/4h1Z5cV Michael Fisch MD MPH

The Dana-Farber Stem Cell Transplant Program is looking to hire a Clinician/ Clinical Investigator to join our team. Please see our ads in TCT, Blood or online and reach out to me if you are interested!

Happy to share this new review on the history and next steps for development of PI3 kinase gamma as a blood cancer target: || PI3Kγ in leukemia: class IB PI3 kinase reemerges as a cancer-intrinsic target ashpublications.org/blood/article-… Qingyu Luo, MD, PhD #AmandaFortune

Leukemia-interested heme/onc fellows - consider joining us as an Advanced Leukemia Fellow! Dynamic and diverse faculty! Dana-Farber Andy Lane H. Moses Murdock Shai Shimony Rahul Vedula Chris Reilly Lachelle Dawn Andrew Hantel Luis E. Aguirre, MD jobcenter.hematology.org/job/14659

Happy to share the first AmericanJournalofHematology #BPDCNsm comprehensive annual review and guidance for BPDCN. Thankful to my colleagues Marlise R. Luskin MD, MSCE Naseema Gangat Angela M. Feraco, MD MMSc Nicole LeBoeuf and Andy Lane onlinelibrary.wiley.com/doi/10.1002/aj…

Is this the end of rivaroxaban for acute VTE? Lana Castellucci presenting the COBBRA trial - 1st RCT comparing apixaban to riva over 3 months. 56% reduction in bleeding risk with apixaban. A safer Rx with the same efficacy. #ISTH2025

#BPDCN is a rare disease with unique clinical, pathophysiologic and therapeutic characteristics. Shai Shimony et al. present an annual review with a framework for diagnosis and managment of BPDCN. doi.org/10.1002/ajh.27… #hemepath #hemonc

Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management onlinelibrary.wiley.com/doi/10.1002/aj… #AML #leusm

🧐Rarity in hematology🧐 Blastic Plasmacytoid Dendritic Cell Neoplasm (#BPDCN) Rare but aggressive blood cancer with a name as complex as its behavior Let's break it down in an educational🧵

Take-home message: BPDCN is rare but deadly❗️ Increased awareness, early diagnosis, and evolving therapies like tagraxofusp, venetoclax and transplant are changing the game❗️ Still, relapse is common❗️ Follow and read Naveen Pemmaraju, MD Shai Shimony and others to learn more❗️

Nico Gagelmann 𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM Gonzalo Bentolila Naveen Pemmaraju, MD The Innovation | Medicine Journal of Brown Hospital Medicine Manual Of Medicine Great thread - check out our review: tinyurl.com/2pkv33d4 Shai Shimony Andy Lane

New Series by Nico Gagelmann: Rarity in Hematology - BPDCN Naveen Pemmaraju, MD Shai Shimony oncodaily.com/insight/nico-g… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #BPDCN #Hematology #RarityinHematology CancerWorld

Happy to present this work that was led by Shai Shimony

Privilege and pleasure to lead this with my Mentor Andy Lane #BPDCN